Market Research Report Global Biosimilar Pipeline Market Report | Page 2

manufacturing challenges, and how strategies based on quality initiatives and risk
management can help address these issues.
Data analyses from our study show there will be enormous commercial opportunities
for biosimilar developers over the coming years, given the number of high-revenue-
generating biologics that will go off patent before 2020, and promising revenue
forecasts for biosimilars in late-stage development. Information leveraged from our
robust industry-leading database highlights a diverse number of biosimilars in the
pipeline for a wide range of therapy areas, with several of these in the later stages of
development. Case studies showcasing strategies adopted by leading pharmaceutical
companies to compete in the biosimilars market are also provided.
Government support for biosimilars is increasing in key geographical markets, given
the cost saving opportunities that these products represent for national healthcare
budgets. Our study details current biosimilar regulatory frameworks and guidelines
implemented in the US, Europe, Japan and China, recent updates regarding the key
issue of interchangeability, and case studies of successful biosimilar approvals in
recent years.
GBI Research conducted extensive research efforts in order to provide a
comprehensive view of the global biosimilar market. This new report adds to our
unique portfolio of trusted industry analyses that enable our clients to assess the most
promising commercial areas in the market and exploit key business opportunities.
Scope
 Global biosimilar pipeline in 2017
 What is the distribution of pipeline biosimilars by stage of development?
 Which are the therapy areas set to benefit the most from biosimilar drugs in
development?
 In biosimilar development, what are the most common molecular targets for
key therapy areas?
 How many companies are currently involved in biosimilar drug development,
which are the most active and what is the level of specialization across the
development landscape?